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Executive Summary
Enhanced Recovery After Surgery (ERAS) guidelines are multimodal perioperative care
pathways based on evidence-based practice to promote faster recovery after surgical procedures.
For cardiac surgery ERAS, one intervention that is strongly recommended based on high levels
of evidence is the use of antifibrinolytic medications, such as Tranexamic acid (TXA) and
epsilon aminocaproic acid (EACA) which are synthetic antifibrinolytics and analogs of lysine,
both known for exerting procoagulant effects by competitively inhibiting activation of
plasminogen to plasmin. Antifibrinolytic medications have been shown to decrease blood loss as
well as the need for blood transfusions and reoperation.
There is strong evidence from the literature for best practices and well-established
international standard ERAS guidelines for cardiac surgery. Reports from key stakeholders in
the pharmacy and anesthesia departments at the project site revealed that the routine use of
antifibrinolytic administration is varied within the cardiac surgical setting. The project team
conducted a chart audit that revealed over a three-month period, only 61% (n= 22/36) of cardiac
surgery patients received an antifibrinolytic. Upon further investigation of the patients that did
not receive an antifibrinolytic, 50% (7/14) of those patients required on pump cardiac surgery
and should have received an antifibrinolytic. A review of the anesthesia records also revealed
variations in dosing among the 22 patients that did receive an antifibrinolytic. 36% (8/22) of
these patients received 10g of EACA, 59% (13/22) received 20g of EACA, and 4% (1/22)
received 10mg of TXA. As a result of the chart audit findings, a clinical practice guideline was
developed for TXA and EACA using the Clinical Guidance Recommendation template at the
institution. The guideline was shared with the Surgery/Anesthesia CPIT Committee for possible
future implementation.
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Introduction
Enhanced Recovery After Surgery (ERAS) protocols are “evidence base practice,
multimodal perioperative care pathways designed to achieve early recovery after surgical
procedures by maintaining preoperative organ function and reducing the profound stress
response following surgery” (Melnyk et al., 2011, p. 342). The literature demonstrates the
implementation of ERAS protocols leads to decreased lengths of stay, postoperative
complications, costs, and increased patient satisfaction (Salenger et al., 2020). In May 2019, the
ERAS Society published 22 recommendations highlighting strategies for preoperative,
intraoperative, and postoperative care for cardiac surgery cases (Engelman et al., 2019). Due to
the extensiveness of the ERAS recommendations, the scope of the Doctor of Nursing (DNP)
Scholarly Project, and needs of the project site, it was determined that one intraoperative
recommendation would be feasible. Therefore, this scholarly project focused on the
administration of antifibrinolytics for patients undergoing on-pump cardiac surgery. The
administration of antifibrinolytics, tranexamic acid (TXA) or epsilon aminocaproic acid
(EACA), during on-pump cardiac surgical procedures is a class IA (strong) recommendation
with a high level of evidence (Engelman et al., 2019). The 2011 American College of Cardiology
Foundation/American Heart Association (AAF/AHA) Guideline for Coronary Artery Bypass
Graft Surgery Executive Summary states “lysine analogues are useful intraoperatively and
postoperatively in patients undergoing on-pump CABG to reduce perioperative blood loss and
transfusion requirements” (Hollis et al., 2011, p. 2624). The 2015 Practice Guideline for
Perioperative Blood Management by the American Society of Anesthesiologists (ASA)
recommends the use of antifibrinolytics for patients undergoing cardiopulmonary bypass to
reduce allogenic blood transfusion (American Society of Anesthesiologists Task Force on
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Perioperative Blood Management, 2015). The 2017 European Association for Cardiothoracic
Surgery (EACTS) guidelines on perioperative medication in adult cardiac surgery and patient
blood management recommend the routine use of antifibrinolytic therapy intraoperatively and
postoperatively to reduce bleeding, transfusions, and reoperations (Sousa-Uva et al., 2018).
While bleeding and transfusion risks are still factors for adverse outcomes of off pump cardiac
surgery, the current guidelines by the Society of Thoracic Surgery for blood conservation do not
include recommendations for off pump cardiac surgery (Gerstein et al., 2017).
Clinical Problem
Despite strong evidence from the literature for best practices and well-established
international standard ERAS guidelines, recent reports from key stakeholders from pharmacy
and anesthesia departments at the project site, a medium sized level one trauma center, revealed
that the use of antifibrinolytic administration was not currently being practiced within the cardiac
surgical setting. Additionally, the anesthesia and pharmacy department stakeholders reported
that a lack of an evidence-based practice guideline may be contributing to the lack of
antifibrinolytics administration in some patients. However, the extent of any clinical data
demonstrating the impacts of this potential clinical problem were unknown at the time. So, the
project team conducted a chart audit to demonstrate a clinical problem and support the need for
the proposed aims of this project. The independent chart audit that occurred between January 1,
2021 and March 31, 2021 demonstrated only 61% (n= 22/36) of cardiac surgery patients at the
facility received an antifibrinolytic. Upon further investigation of the patients that did not receive
an antifibrinolytic, 50% (7/14) of these patients required on pump cardiac surgery and should
have received an antifibrinolytic. A review of the anesthesia records revealed variations in
dosing among the 22 patients that did receive an antifibrinolytic. 36% (8/22) of these patients

5
received 10g of EACA, 59% (13/22) received 20g of EACA, and 4% (1/22) received 10mg of
TXA.
Optimizing standardization is important to avoid clinical practice errors and
complications to patient health through the perioperative period. Cardiac surgery patients who
did not receive antifibrinolytics intra-operatively may be at an increased risk for bleeding,
administration of blood transfusions, and reoperation for major hemorrhage or cardiac
tamponade. A large, randomized control trial showed decrease in blood transfusion, major
hemorrhage, cardiac tamponade, and reoperation in patients who received TXA (Engelman et al.,
2019). There is high-level, class-IA evidence from the scientific and clinical literature that
suggests the use of antifibrinolytics as best practice (Engelman et al., 2019). Consequently, the
lack of a standardized guideline and variability of clinical practice validated by recent chart
audits may indicate an increased risk to cardiac surgical patients. Therefore, an opportunity
existed for this project team to provide the hospital leadership with EBP recommendations and a
standardized ERAS-based guideline. This would help streamline process and improve the
quality and consistency of ERAS guided practices involving antifibrinolytic medications in
cardiac surgical patients.
Significance to Nurse Anesthesia
Anesthesia care of cardiac surgery patients throughout the perioperative period requires
an up-to-date, evidence-based, dedicated team approach. The most life-threatening event
associated with cardiac surgery is often bleeding complications (Leff et al., 2019). Cardiac
surgery patients frequently require blood transfusions and use approximately 20% of the blood
supply in the United States (Leff et al., 2019). A cardiac surgery patient that is adversely
bleeding requires increased staffing resources in the intensive care unit as well as the operating
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room. Antifibrinolytic medication administration, with tranexamic acid (TXA) and/or epsilon
aminocaproic acid (EACA), decreased the amount of blood products transfused to the patient and
decreased the incidence of reoperation for major hemorrhage and cardiac tamponade (Engelman
et al., 2019). Lastly, recommendations on the administration of antifibrinolytics for on-pump
cardiac surgery may assist, with ERAS guideline implementation, the project hospital site in
optimizing intraoperative team workflow.
EBP Guideline Development
Informal multidisciplinary interviews with an on-site clinical pharmacist and
anesthesiologists revealed that ERAS guidelines for cardiac surgery are not common practice.
Due to the vast amount of ERAS recommendations for cardiac surgery patients, a comprehensive
Cardiac Surgery ERAS guideline was not feasible to complete due to the project’s
academic/curricular limitations. Therefore, the project focused on one aspect of Engelman et al.
(2019) based on project site needs. There was a lack of a standardized guidelines for
administration of antifibrinolytic medication for elective, on pump cardiac surgery. A clinical
practice gap existed between the current practice at the facility and the EBP recommendations of
the ERAS Cardiac Surgery Society and the Society of Thoracic Surgery Blood Conservation.
The project team worked with key stakeholders in the pharmacy and anesthesia departments at
the project site to develop an EBP protocol that represents best practice guidance and meets the
needs of the institution.
Project Scaffolding
The project site lacked a standardized guideline for antifibrinolytic medication
administration for on pump cardiac surgery. After completing a chart review, a clinical practice
gap was identified between current practice and evidence-based practice recommendations by
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the ERAS Cardiac Surgery Society regarding antifibrinolytic administration for patients
undergoing on pump cardiac surgery. Of the patients that did not receive an antifibrinolytic, 50%
of those patients went on cardiopulmonary bypass and should have received an antifibrinolytic
medication intraoperatively. Reports from stakeholders in the pharmacy and anesthesia
departments at the facility indicated that the lack of an evidence-based practice guideline may
have been a contributing factor to the lack of antifibrinolytics administration in some cardiac
surgical patients. Consequently, the lack of standardized guidelines and variability of clinical
practice validated by the chart audit indicated a possible increased risk to cardiac surgical
patients for adverse outcomes.
Purpose
The purpose of this project was to develop, for hospital leadership, a standardized
evidence-based practice guideline for administration of TXA and EACA using the project site’s
Clinical Guidance Council Recommendation Template. The following objectives and methods
were framed using the Knowledge to Action Framework and have been established to achieve
the project’s overall aim: 1) review and synthesize the evidence from the literature around the
use of ERAS guided antifibrinolytic medication practices in cardiac surgical patients, 2) develop
a standardized, evidence-based, clinical practice guideline for administration of antifibrinolytics
for on pump cardiac surgeries, and 3) submit the guidelines to the Clinical Process Improvement
Team (CPIT) and present our recommendations to key stakeholders utilizing a SWOT format.
Evidence-Based Practice Framework
Knowledge to Action Framework
The conceptual framework that was used to guide this project was the Knowledge to
Action (KTA) framework developed by Graham et al. (2006) and shown in Figure 1. The KTA
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framework has been used to facilitate the development and application of research evidence into
clinical practice. Williams et al. (2019) used this framework to synthesize ERAS data from other
specialties, identify gaps within the cardiac surgery specialty, and apply the knowledge gained to
cardiac surgery. The KTA process consists of the knowledge creation cycle and the action cycle.
Figure 1. Illustration of Graham et al. (2006) Knowledge to Action Framework
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Knowledge Creation Cycle. Regarding this project, the knowledge creation aspect
(Figure 1) of KTA is demonstrated by the evidence synthesis table (see Appendix A), and this is
described as knowledge inquiry, knowledge synthesis, and knowledge tools/products. Field et al.
(2014) describes that KTA is “…used in practice with varying degrees of completeness” (Field et
al. 2019; p. 6).
Action Cycle. This phase was conducted by reviewing and synthesizing the evidence
from the literature around the use of ERAS guided antifibrinolytic medication practices in
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cardiac surgical patients, developing a standardized evidence-based practice guideline for
administration of antifibrinolytics for on pump cardiac surgeries, and submitting the
guideline/recommendation to the Clinical Process Improvement Team (CPIT) and key
stakeholders. Identify, review, and select knowledge was completed through an extensive
literature search around the use of ERAS guided antifibrinolytic medication practices in cardiac
surgical patients and also the comparative state of current practices which consisted of nonstandardized intraoperative antifibrinolytic practices for cardiac surgical patients. Adapt
knowledge to local context involved discussing literature findings and using provided data from
retrospective chart audits with personnel from pharmacy, anesthesia, and the Clinical Practice
Improvement Team (CPIT). Assessing barriers to knowledge use was completed through the
process of developing the clinical practice guideline and meeting with pharmacy and anesthesia
stakeholders. The project site’s Clinical Guidance Council Recommendation template was
utilized (Appendix B). Moreover, a presentation was created and presented along with the
guideline draft to key stakeholders, pharmacy, anesthesia, and the Clinical Process Improvement
Team (CPIT) utilizing a SWOT format.
The aspects of the KTA cycle (per Figure 1) were to identify a problem, identify, review,
select knowledge; adapt knowledge to local context; and assess barriers to knowledge use. For
the scope of this project, the team did not intend to execute the following KTA framework steps:
the implementation of interventions, monitoring knowledge use, evaluation of outcomes, and
sustainment of knowledge use.
Strengths, Weaknesses, Opportunities, and Threats Analysis
A SWOT analysis (See Appendix C) briefing format was used to present the best
evidence from literature and make recommendations for future use of ERAS guided
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antifibrinolytic therapy in cardiac surgical patients. A SWOT analysis is a process of identifying
a company's Strengths, Weaknesses, Opportunities, and Threats (Moran et al., 2018). The
strength component focused on current processes and patient outcomes which measures the
quality of care being delivered. The weakness component looked at current processes and patient
outcomes that might have indicated certain downfalls of the process. The opportunity component
further explored the desired state of practice and patient outcomes related to ERAS guidelines
and evidence from the literature. The threat component addressed barriers or individual
reluctancy to future ERAS guideline implementation. The SWOT analysis helped stakeholders
and clinical practice improvement leaders develop a full awareness of all the factors involved in
ERAS guided practices using antifibrinolytics in cardiac surgical patients at the facility.
Ethics and Considerations/ Protection of Human Subjects
Following the project proposal’s review and approval by the project site’s Nursing
Evidence-Based Practice Committee (NEBPRC), the approval letter (see Appendix D), proposal,
and application were submitted to the Otterbein University Institutional Review Board (IRB).
Once approval was obtained from the Otterbein University IRB, the official IRB determination
document (see Appendix E) was submitted to the OH NRC for record-keeping. As previously
mentioned, no names or unique patient/staff identifiers were requested, collected or stored. No
personal health information (PHI) was collected. All collected information was fully deidentified prior to storage into a password-protected, secure spreadsheet. Only de-identified
aggregate data was shared outside of the project site with Otterbein University Nursing
Department faculty and students as part of dissemination of the DNP Final Scholarly Project
Report presentation.
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Literature Review and Synthesis
The PICO format provided a framework for examining and answering a specific question
related to the previously described problem (Melnyk & Fineout‐Overholt, 2005). The PICO
format was used to develop the clinical question as well as provide strategic keys search terms to
obtain the best evidence related to the problem. The four components include “population of
interest [P], intervention of interest [I], comparison of interest [C], and outcome of interest [O]”
(Melnyk & Fineout‐Overholt, 2005, p. 29). The population and problem of interest for this
project was centered on adult patients undergoing elective, on-pump cardiac surgery, and did not
receive antifibrinolytics intra-operatively. The intervention of interest was focused on the use of
standard ERAS guidelines in the intra-operative administration of antifibrinolytics for cardiac
surgery patients. The comparative state focused on the current practice which consisted of nonstandardized intraoperative antifibrinolytic practices for cardiac surgical patients. The outcomes
of interest included the following: patient blood loss, blood transfusion requirement, re-operation
following cardiac surgery, seizure activity, fibrinolytic lab, and costs associated with length of
hospital stay. The PICO question was as follows: “(P) In patients who undergo elective, on-pump
cardiac surgery, and do not receive antifibrinolytics intra-operatively, how does the use of (I)
standard ERAS guidelines in the intra-operative administration of antifibrinolytics compared (C)
to the current, non-standardized antifibrinolytic practices affect (O) patient blood loss, blood
transfusion requirement, and re-operation following cardiac surgery?”
A search for relevant literature pertaining to intraoperative administration of
antifibrinolytic medications during cardiac surgery was conducted. Database resources utilized
through OneSearch included CINAHL, Cochrane Library, MEDLINE, and PubMed. Keywords
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used included cardiac surgery, ERAS, enhanced recovery after surgery, antifibrinolytics,
tranexamic acid, TXA, epsilon aminocaproic acid, EACA, bleeding, and blood transfusion.
Articles were screened for relevance and 15 articles were selected based on inclusion of
antifibrinolytics therapy, cardiac surgery patient population, on pump cardiac procedures, and
strength of the studies. The 15 articles selected included seven systematic reviews and metaanalyses (Boer et al., 2020; Engelman et al., 2019; Guo et al., 2020; Habbab et al., 2020; Khair et
al., 2019;Levy et al., 2020; Zufferey et al., 2021), five randomized control trails (Fergusson et
al., 2008; Leff et al., 2019; Myles et al., 2017; Raghunathan et al., 2011; Zhou et al., 2021), two
cohort studies (Blaine et al., 2016; Williams et al., 2019), and one observational study (Strauss et
al., 2021). Further details regarding each article can be found in the Review of Evidence and
Synthesis Table, which also includes an appraisal for each of the article's strengths, limitations,
risks, and feasibility (see Appendix A).
Related Research
ERAS Beginnings and the Cardiac Surgery Field. Enhanced Recovery After Surgery
(ERAS) programs challenge the status quo of the perioperative pathway and have gained
significant support since the first ERAS Society supported US symposia on ERAS was held by
Duke University in 2013 (ERAS Society, 2020). The ERAS Society started as an ERAS Study
Group in 2001, comprised of leading surgeons, and officially registered as a non-profit medical
society in 2010 based out of Stockholm, Sweden. The mission of ERAS programs is to modify
the perioperative care process to improve patients’ recovery through research, education, audit,
and implementing evidence-based practice (ERAS Society, 2020).
ERAS guidelines have been published throughout the 2010s for colorectal surgery,
bariatric surgery, breast reconstruction, head and neck cancer surgery, and gynecological
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surgery. The cardiac surgery specialty was updated by Engelman et al. (2019), with the first
expert-consensus review of evidence-based cardiac surgery ERAS practices. 197 studies were
ultimately included in the meta-analysis and a formal ERAS Cardiac Society was created and
aligned with the ERAS Society to develop the new guidelines. The ERAS Cardiac Society was
comprised of 16 cardiac surgeons, anesthesiologists, and intensivists who were knowledgeable
and experienced with ERAS. Twenty-two potential interventions were agreed upon and divided
by phase of care. This scholarly project was ultimately motivated by Engelman and colleagues’
(2019) guidelines as they were recognized to be critical to patients receiving elective cardiac
surgery.
ERAS Recommendations for Antifibrinolytic Therapy. Engelman et al. (2019)
recommended that TXA or EACA should be administered during on-pump cardiac surgical
procedures, due to literature showing reduced total blood products transfused and reoperation for
major hemorrhage or cardiac tamponade. Seizures have been dose-dependently implicated with
administration of TXA, and the maximum total dose from Engelman et al. (2019) is 100 mg/kg.
Additionally, Engelman and colleagues (2019) recommended the comprehensive, multi-societal,
clinical practice guidelines published by Boer et al. (2018) regarding patient blood management.
Boer et al. (2018) developed the 2017 guidelines by forming a task force composed of the
European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of
Cardiothoracic Anaesthesiology (EACTA). The 2017 EACTS/EACTA guidelines were
recommended to be utilized by Engelman et al. (2019) due to reduced bleeding and transfusions
of blood products, and decreased incidence of reoperation for bleeding.
Bleeding. A meta-analysis of randomized controlled trials by Guo et al. (2019),
evaluating 49 studies and 10,591 adult patients, demonstrated a significant reduction in post-
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operative blood loss in patients receiving intravenous tranexamic acid. Post-operative blood loss
was evaluated in 44/49 studies and the average reduction in blood loss was approximately 247
mL per patient compared to control. The blood loss findings by Guo et al. (2019) are further
supported by Myles et al. (2017). Myles and colleagues conducted a randomized controlled trial
of adult patients undergoing coronary artery surgery at risk for perioperative complications.
4,631 patients had available outcome data, and patients either received intravenous TXA or
placebo. Dosing ranged from 50 mg/kg to 100 mg/kg throughout the trial. The TXA group had a
significantly reduced number of patients that had blood loss during surgery, though specific
averages were not provided. A meta-analysis by Habbab et al. (2020), including seven
randomized controlled trials and 692 total patients, evaluated the intrapericardial approach of
administering TXA. The results of Habbab and associates further support the literature that TXA
administration, albeit a different route in this meta-analysis, decreases blood loss for adult
patients undergoing cardiac surgery. Overall, patients receiving topical TXA experienced a
significant reduction in 24-hour blood loss on average of about 350 ml. Zufferey et al. (2021)
conducted a model-based meta-analysis that included 64 randomized controlled trials total, and
56 reported post-operative blood loss. Zufferey and colleagues reported that TXA usage was
associated with a maximum effect of reducing blood loss by forty percent.
The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) study
was a multi-center, randomized control trial conducted from 2002 until 2007 comparing
aprotinin to the lysine analogs, TXA and EACA (Fergusson et al., 2008). A total of 2,331 high
risk cardiac surgery patients were randomly assigned to one of the three groups to receive a
specific antifibrinolytic: 781 received aprotinin, 770 received tranexamic acid, and 780 received
aminocaproic acid (Fergusson et al., 2008). The original hypothesis was that aprotinin would be
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superior to the lysine analogs in reducing massive postoperative bleeding. Fergusson et al.
(2008) defined massive postoperative bleeding for the BART trial as output greater than 1.5L
over eight hours. Of the 780 patients in the EACA group, 94 patients (12.1%) met the criteria for
massive bleeding. In comparison, patients in the TXA group had similar results with 93 of 770
patients (12.1%) that met the massive bleeding criteria (Fergusson et al., 2008). While the rate of
massive bleeding was similar in both groups, the EACA group had less patients die secondary to
hemorrhage. Four patients died in the EACA group compared to eight patients in the TXA group
(Fergusson et al., 2008). A small, single-center, double-blinded and randomized trial comparing
TXA and EACA, included 114 patients undergoing on pump cardiac surgery to evaluate
bleeding and transfusion postoperatively (Leff et al., 2019). Chest tube output was measured at
four, six, twelve, and twenty-four hours postoperatively and again there was no statistically
significant difference in the median output of the two groups.
Blood Transfusion Requirements. Blood transfusion requirements are reduced for adult
patients undergoing cardiac surgery who receive TXA. Guo et al. (2019) examined transfusion
rate related to on and off-pump cardiac surgery, types of surgery, type of administration, and
amount of dose. Transfusion need was significantly reduced for off-pump cardiac surgery, onpump cardiac surgery, patients undergoing CABG, and patients undergoing other surgeries. In
patients receiving TXA intravenously, transfusion requirements were significantly reduced.
Patients receiving TXA bolus or TXA bolus plus continuous infusion had a significant reduction
in transfusion needs. Low-dose (≤10 mg/kg + 1 mg/kg/h), high-dose TXA bolus plus continuous
infusion, low-dose bolus alone, and high-dose bolus alone significantly reduced transfusion
needs. Myles et al. (2017) also showed decreased amount of the number of blood transfusions
and a decreased number of patients who received a blood transfusion for patients receiving TXA
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compared to control. Patients who received TXA were administered 46 percent fewer blood
products, which could equate approximately to saving 57 units of blood products per every 100
patients treated. Habbab et al. (2020) were able to evaluate topical TXA administration and
transfusion requirements in 6/7 trials of the meta-analysis. One study yielded a significant
reduction in the incidence of packed RBC transfusion, while the other five studies did not show a
significant reduction but showed a trend in favor of topical TXA. Though one study differs, the
findings of five studies not showing a statistically significant difference in decreased blood
transfusion rate by Habbab et al. (2020) parallel the findings of Guo et al. (2019) regarding
topical TXA as this intervention did not reduce transfusion requirements in Guo’s (2019) metaanalysis.
When comparing TXA to EACA in regard to transfusion outcomes and massive
transfusion postoperatively, the BART study conducted by Fergusson et al. (2008) found no
statistical differences. Over 60% of patients in both the TXA group and EACA group required at
least one unit of packed red blood cells: 506 of 770 (65.7%) in the TXA group and 514 of 780 in
the EACA group (65.9%). Fergusson et al. (2008) defined massive transfusion as the
administration of greater than ten units of packed red blood cells. The TXA group had 17 of 770
patients (2.2%) compared to the EACA group with 22 of 780 patients (2.8%) require massive
transfusion (Fergusson et al., 2008). In 2013, there was a shortage of EACA and institutions that
typically used EACA had to switch to TXA (Blaine et al., 2016). The medication shortage
provided an opportunity to do additional comparative studies with retrospective data. The single
center study by Blaine et al. (2016) included 128 patients: 60 received TXA prior to the
medication shortage and 68 received EACA after the medication shortage. Results from Blaine
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et al. (2016) study was like Fergusson et al. (2008) and no statistical differences in bleeding or
transfusion requirements were found through multivariate analysis.
Unlike the other studies, Leff et al. (2019) found that the TXA group was 2.4 times more
likely to require a blood transfusion within the first 24 hours. The percentage of patients in the
TXA group that required transfusion was 44.8%, while the EACA group was 25%. The types of
blood products each group received were also evaluated. This evaluation revealed that 35.4% of
the TXA group required transfusion of packed red blood cells and 17.2% required fresh frozen
plasma. Comparatively, only 17.9% of the EACA group required packed red blood cells and
5.4% required fresh frozen plasma. Several limitations exist in this study because it was a singlecenter study with a small sample size. Their analysis also included trust scores that assessed
patients’ risks for requiring transfusions. The trust scores revealed a higher risk in the TXA
group which could explain why more transfusions were necessary. Nonetheless, the study still
supported the use of either EACA or TXA for on-pump cardiac surgery patients to reduce
bleeding and blood transfusions (Leff et al., 2019).
Cost. Considering the similarities in clinical efficacy and safety of both EACA and TXA,
the costs of each medication and local factors of the institution that influence costs should be
considered when determining best practices for an institution. During the creation of practice
protocols, the effects of medication shortages must also be considered. During a medication
shortage, Blaine et al. (2016) found no difference between TXA and EACA in regard to bleeding
and transfusion, however, the EACA group was more likely to receive rescue hemostatic
medications such as recombinant factor VIIa and desmopressin. A single unit of packed red
blood cells can cost $467 to $1,055 in the United States and the rescue medications can cost
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several thousand (Blaine et al., 2016). In these scenarios, TXA could be more cost-efficient if
rescue medications can be avoided (Blaine et al., 2016).
In 2011, Raghunathan et al. (2011) revaluated data from the BART trial to compare the
“clinical value” of EACA and TXA. While clinical outcomes such as postoperative bleeding and
mortality are of utmost importance, cost considerations can be vital when clinical outcomes are
similar. Raghunathan et al. (2011) define clinical value as the “function of quality divided by
costs and then multiplied by volume,” with volume referring to number of uses (p. 18). Dosing
for the BART study included a loading dose followed by a continuous infusion for both lysine
analogs. The EACA regimen included a 10g loading dose, followed by 2g per hour infusion
(Fergusson et al., 2008). The TXA regimen included a 30mg/kg loading dose, followed by
16/mg/kg/h continuous infusion. An additional 2mg/kg of TXA was also added to the bypass
circuit (Fergusson et al., 2008). At the author’s institution, TXA was 225 times more expensive
than EACA for an 80kg patient undergoing a five-hour surgery (Raghunathan et al., 2011). TXA
cost was $540 while the cost for EACA was only $2.40. After the clinical value equation was
applied to this data, the author’s institution changed the policy to administer EACA for all cases.
The change in antifibrinolytics led to $100,000/year in cost savings, while anecdotally, bleeding
rates and blood transfusions did not change (Raghunathan et al., 2011). Leff et al. (2019) also
described the cost differentials between the two antifibrinolytic medications but mentioned
different dosing costs. According to Leff et al. (2019), TXA is only 30 times more expensive at
$30-100 per dose compared to EACA at $11-30 per dose. Leff et al. (2019) is a more current
study and could represent more accurate costs for 2020. The cost of the medication, blood
products, rescue medications, and reoperation are all essential factors to consider when
evaluating costs.

19
Reoperation After Cardiac Surgery. Reoperation data for Guo and colleagues (2019)
was available in 32 of 49 trials, totaling 8,937 patients. TXA administration significantly reduced
risk of reoperation by 38 percent. Reoperation rates were 2.4 percent and 3.9 percent for TXA
and control groups, respectively. Likewise, Myles et al. (2017) observed a significant reduction
in reoperation for major hemorrhage or cardiac tamponade with intravenous TXA. Reoperation
rates were 1.4 percent and 2.8 percent for TXA and placebo groups, respectively. The number
needed to treat is the number of patients that need to receive a drug or intervention to see oneperson benefit. In Myles et al. (2017), 71 patients were the number needed to treat to prevent one
reoperation within 30 days. There was not enough data from Habbab et al. (2020) to determine if
topical TXA administration reduced the need for reoperation after cardiac surgery.
When comparing reoperation data between TXA and EACA, outcomes were similar
across several studies. The reoperation rates when TXA was compared to EACA in the BART
study, were 8.1 percent for TXA and 8.2 percent for EACA (Fergusson et al., 2008). No
differences in reoperation were also found by Leff et al. (2019). Reoperation within the first 24
hours after surgery occurred in 4 of 58 patients in the TXA group while reoperation occurred in 3
of 56 patients in the EACA group (Leff et al., 2019). In both groups during reoperation, one
patient had an identifiable source of bleeding. The other patients in both groups had no
identifiable source of bleeding and the cause of blood loss was determined to be related to
coagulopathy (Leff et al., 2019).
Patient Outcomes and Complications. ERAS recommendations are provided to
optimize a patient’s perioperative experience, emphasizing reduced complications and length of
stay. The concern around TXA administration is the potential for thromboembolic events such as
myocardial infarction, stroke, pulmonary embolism, renal failure, and bowel infarction, as well
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as seizures or death. (Engelman et al., 2019; Myles et al., 2017). Guo et al. (2020) observed no
statistical difference between TXA administration and control in MI, stroke, pulmonary
embolism, renal dysfunction, and mortality. Seizure was evaluated in 11 trials, totaling 6,784
patients. TXA was associated with a 3.21-fold increase in the risk of seizure. Seizure occurrence
was 0.62 percent (21/3,378) for patients receiving TXA and 0.15 percent (5/3,406) for control
groups. Importantly, none of the patients receiving low dose TXA intravenously experienced a
seizure, whereas patients receiving high-dose TXA did experience seizure in Guo et al. (2019).
Guo and colleagues’ (2019) findings regarding seizure differences with dosing differs from
Myles et al. (2017). Seizure occurrence was noted as a higher risk in the TXA group, but a dose
reduction to 50 mg/kg (from 100 mg/kg) did not decrease seizure risk, though the sample size is
underpowered. The number needed to harm, similar to number needed to treat but for causing
one additional patient to experience a seizure, was 177 patients. Interestingly, the incidence of
seizure in patients undergoing open-chamber heart surgery that received TXA was statistically
significant compared to placebo, whereas no statistical significance was observed in seizure
incidences for patients undergoing isolated coronary artery surgery that received TXA compared
to placebo (Myles et al., 2017). Leff et al. (2019) was not powered to evaluate seizure risk
related to the administration of TXA and EACA, however, it is noted that no seizures were
observed in either group. Myles and associates (2017) demonstrated similar outcomes to Guo et
al. (2020), with no significant difference between TXA and control in MI, stroke, pulmonary
embolism, renal failure, bowel infarction, and mortality within 30 days of surgery. Comparing
TXA and EACA, Fergusson et al. (2008) and Leff et al. (2019) had similar adverse event
outcomes related to stroke, myocardial infarction, renal dysfunction, and rates of organ failure.
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The EACA group had a decreased incidence of stroke and MI but had an increased incidence of
cardiogenic shock compared with the TXA group (Fergusson et al., 2008).
Habbab et al. (2020) reported one trial with no difference in post-operative complications
regarding topical TXA and control groups, including seizure. TXA dosage ranged from 1 to 2.5 g
diluted in 100 to 250 mL of 0.9% NaCl or only 0.9% NaCl as a placebo. The TXA or placebo
was poured before sternal closure into the pericardial cavity and over the mediastinal tissues.
Topical TXA may not be absorbed systemically following administration due to the natural
barrier that the pericardium acts as. Decreased systemic absorption could conceivably decrease
seizure incidence compared to intravenous administration. TXA levels were not detected in a
small patient group that received topical TXA. Mortality was not observed for either group in 3/7
trials or 3 other trials did not provide data for mortality.
Mechanical ventilation time was slightly decreased in the TXA group of Myles and
colleagues (2017) but was not associated with an earlier discharge from the hospital. Habbab et
al. (2020) reported a significant reduction in intensive care unit length of stay in 2/4 studies that
provided data. Additionally, hospital length of stay data was provided for 3/7 studies and did not
show significant differences. Length of stay data was not provided in Guo et al. (2020). Length
of stay was evaluated in the BART study for the intensive care unit as well as total hospital stay.
The median ICU length of stay was 1.5 days in the TXA group and 1.8 days in the EACA group
(Fergusson et al., 2008). The total hospital length of stay median was 8.5 days in the TXA group
and 8.0 days in the EACA group (Fergusson et al., 2008).
Optimal Dosing. The optimal dose of TXA for use in cardiac surgery is reviewed by
Levy et al. (2018) and Zufferey et al. (2021). Generalized convulsive seizures were associated at
high doses of TXA at 100 mg/kg. One TXA dosing strategy that achieved 100 percent
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antifibrinolytic activity was a loading dose of 30 mg/kg followed infusion at 16 mg/kg/hr for six
hours with 2 mg/kg added to the cardiopulmonary bypass pump prime, which is referenced by
Zufferey et al. (2021) as high-dose TXA. Zufferey et al. (2021) and Zhou et al. (2021)
distinguish that a platform effect occurs with TXA, meaning higher doses do not yield additional
benefit, rather they pose additional harm to patients. An 80 percent effective concentration is
stated to reduce postoperative blood loss and red blood cell transfusion (Zufferey et al., 2021).
Low-dose TXA can achieve close to 80 percent effective concentrations by a pre-operative bolus
of 20 mg/kg or 10 mg/kg followed by 1 mg/kg/h for 12 hours. The total TXA dose should be
roughly 20 mg/kg (Zufferey et al., 2021). Zhou et al. (2021) suggest low-dose TXA to patients
with a low bleeding risk undergoing valvular cardiac surgery with cardiopulmonary bypass, as
low-dose TXA was equivalent to high-dose TXA in in-vivo fibrinolysis parameters. A large
meta-analysis and systematic review regarding the exclusion criteria for TXA administration in
cardiac surgery patients concluded that perioperative intravenous TXA in cardiac surgery
patients did not increase the overall risk of adverse events compared with placebo, no
intervention, or EACA. Patients with renal impairment may need alternate dosing due to longer
elevation of systemic TXA levels, however, routine anticoagulant and anti-platelet medications
are thought to negate this concern (Khair et al., 2019)
Dosing for the BART study included a loading dose followed by a continuous infusion
for both lysine analogs. The EACA regimen included a 10g loading dose, followed by 2g per
hour infusion (Fergusson et al., 2008). The first 200mg of the loading dose were given as a test
dose, followed by 9800mg if no anaphylactic reaction was observed (Fergusson et al., 2008). The
TXA dosing regimen described by Levy et al. (2018) is identical to the schedule used by
Fergusson et al. (2008) in the BART study. TXA dosing included a 30mg/kg loading dose,
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followed by 16mg/kg/h continuous infusion. The 30mg/kg loading dose was diluted into 250ml
and given over 10 min after a 5 ml test dose was administered (Fergusson et al., 2008). An
additional 2mg/kg of TXA was also added to the bypass circuit (Fergusson et al., 2008). The
dosing schedule used in the BART study by Fergusson et al. (2008) was replicated by Leff et al.
(2019).
A slightly different dosing regimen was used by Blaine et al. (2016). Prior to the shortage
of EACA, patients undergoing cardiac surgery at the institution received EACA. An initial
loading dose of 10-15 mg/kg was given over 10-15 min followed by an infusion for 6 hours at 12mg/kg/hour (Blaine et al., 2016). The same loading dose and infusion rate was used during the
medication shortage for TXA administration. The loading doses for the bypass circuit differed
slightly between the two medications. The EACA bolus for the bypass circuit was 2-3mg/kg
while the TXA dose was 2-2.5mg/kg (Blaine et al., 2016).
While most of the studied dosing regimens for EACA include a bolus or loading dose,
followed by an infusion, a recent study examined the efficacy of a two-bolus regimen of EACA.
The goal for antifibrinolytic dosing during cardiac surgery is to maintain plasma levels of EACA
greater than 130mg/L (Strauss et al., 2021). The regimen studied at by Strauss et al. (2021)
included a 1g/hr infusion started after central line placemen continued for 5 hours. The infusion
was then followed by a 5g bolus for the cardiopulmonary bypass circuit as well as 5g bolus prior
to protamine administration (Strauss et al., 2021). The first bolus helps protect against
fibrinolysis during cardiopulmonary bypass, while the second bolus protects fibrin formed after
protamine administration. Out of 21 patients in the study, 16 patients-maintained concentrations
greater than 130mg/L (Strauss et al., 2021). However, five of the 21 patients fell below the target
plasma concentration prior to the second bolus given prior to protamine administration (Strauss
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et al., 2021). This study contained a small sample size with limitations and therefore further
pharmacokinetic and pharmacodynamic studies are needed to improve EACA dosing regimens.
Guideline Development
Summary of Relevant Literature
The use of TXA and EACA in adult patients undergoing on-pump cardiac surgery has
shown considerable benefit to patients, classified as I-A by Engelman et al. (2019) as the benefit
is much greater than the risk. Intravenous TXA and EACA as well as topical routes of TXA have
both been used successfully to decrease the amount of blood loss after cardiac surgery, though
optimal dosing is not currently established. Higher intravenous dosing of TXA, ≥ 100 mg/kg
appears to be associated with incidences of seizure. More research is needed to determine further
safety and efficacy of the impact of topical TXA on blood transfusion needs and post-operative
outcomes. Intravenous TXA and EACA appears to show promise in decreasing blood transfusion
needs in cardiac surgery patients and does not statistically differ from control groups in regard to
post-operative outcomes. Decreasing the amount of blood transfusions to patients could create
more opportunities for other patients to receive blood products, which could be very beneficial to
an underserved, level-one trauma center that provides care frequently to at-risk patients with
multiple comorbidities. Streamlining TXA and EACA administration could also provide costsavings by decreasing incidences of reoperation following cardiac surgery.
The efficacy of antifibrinolytic use for on-pump cardiac surgery is well understood and
the evidence supports the use of both lysine analogs to decrease postoperative bleeding and
blood transfusions. There has not been a definitive recommendation for one over the other. The
choice of lysine analogs can vary due to hospital formulary, regional practices, pharmacy

25
contracts, surgical case volume, and patient population. All local factors should be considered
when determining best practice for an institution.

Project Outcomes and Evaluation
TXA SWOT Analysis and Guideline Recommendation
Strengths. Administration of TXA for on-pump cardiac surgical procedures was
designated as a I-A recommendation by the Cardiac ERAS Society due to a reduction in total
blood products transfused and a reduction in reoperation for major hemorrhage or tamponade.
Utilizing a weight-based, low-dose strategy appears to be safe in regard to the possible adverse
effect of seizure. In the event of a shortage of Amicar, this suggested guideline can help direct
practitioners how to administer TXA.
Weaknesses. A consensus on the dosing regimen for TXA administration for on-pump
cardiac surgical procedures does not exist, therefore, the guideline recommendation is based on
thorough literature review. There was only one patient that received TXA from the data set and
TXA is not commonly administered for cardiac surgical procedures, making it difficult to assess
TXA administration practices.
Opportunities. A large, double-blinded, randomized controlled trial by Shi and
colleagues that is designed to identify the TXA dose with maximal efficacy and minimal
complications in cardiac surgery patients is scheduled to be completed by December 31st 2021.
The results from Shi et al. could further help the project site determine TXA dosing for cardiac
surgical procedures. Education to the peri-operative cardiac surgery team on the possible benefits
of low-dose TXA administration strategies could help increase the team’s comfort when utilizing
TXA for future cardiac surgeries.
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Threats. TXA has documented possible adverse effects of concern in the literature,
importantly seizure and stroke. Though the adverse effects appear to be dose-dependent in the
high-dosing strategy and TXA has documented benefits mentioned above, the risks may deter
providers from administering TXA to cardiac surgical patients. Additionally, cardiac surgeons
had the ability to dictate medications given by anesthesia which can limit changes in practice to
reflect evidence base practice recommendations. One surgeon at the project site did not support
the use of antifibrinolytics. The CPIT committee would need buy in from both the cardiac
surgeons and anesthesiologists to create a change in practice that will be followed.
Guideline Recommendation. Based on the literature review and synthesis, the chart
audit at the project site, as well as stakeholder input: the following EBP Guideline
recommendations were formulated for the administration of TXA for on-pump cardiac surgery
(See Appendix F). A low-dose strategy of approximately 20 mg/kg, either: 10 mg/kg bolus
followed by 1mg/kg/hr over 12 hours or a single pre-operative bolus of 20 mg/kg. This contrasts
from the current project site guideline of a 1g loading dose administered before sternotomy
followed by a constant infusion at 400 mg/hr until sternal closure. This low-dose strategy may
provide a safer profile for patients and be just as efficacious in reducing blood products
transfused, post-operative bleeding, and re-operation rates. The same dose reduction is
recommended for patients with renal impairment due to a lack of literature regarding dosing in
this population.
EACA SWOT Analysis and Guideline Recommendation
Strengths. EACA is the main antifibrinolytic used at the project site for cardiac surgery
patients. Recommendations from multiple professional organizations support the routine use of
antifibrinolytic therapy for on pump cardiac surgery procedures. Current practice at the project
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site included a 10g bolus of EACA after induction of anesthesia followed by a 10g bolus of
EACA after cardiopulmonary bypass. One surgeon used EACA for all on pump cardiac surgery
procedures.
Weaknesses. The chart audit revealed that of the 14 patients that did not receive an
antifibrinolytic, seven of the patients should have received an antifibrinolytic because the
procedure required cardiopulmonary bypass. A variation in dosing was also identified among the
patients that did receive EACA intraoperatively. Review of the anesthesia record revealed that
36% (8/22) of the patients received 10g of EACA while 59% (13/22) received 20g of EACA.
Omitting the second bolus dose of EACA could be putting patients at risk of falling below the
therapeutic plasma level of EACA during a critical time of fibrin formation post
cardiopulmonary bypass after the administration of protamine.
Opportunities. The findings of this project served as a starting point to improve the
quality and consistency of EACA dosing for the cardiac surgery population. There is an
opportunity to improve on the administration of EACA for all patients that require on pump
cardiac surgery as well as improved consistency for dosing among providers.
Threats. Cardiac surgeons had the ability to dictate medications given by anesthesia
which limited changes in practice to reflect evidence base practice recommendations. One
surgeon at the project site does not support the use of antifibrinolytics. The CPIT committee will
need buy in from both the cardiac surgeons and anesthesiologists to create a change in practice
that will be followed.
Guideline Recommendation. Based on the literature review/synthesis, chart audit and
stakeholder input, the following EBP Guideline recommendations were formulated for the
administration of EACA for on pump cardiac surgery (See Appendix F). The dosing regimen
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used at the project site should be changed from a two-bolus dose to a regimen that reflects dosing
studied more consistently in the literature. The new dosing recommendation is a bolus of 10g
followed by an infusion of 10-15mg/kg/hr. This dosing regimen reflects current pharmacy
recommendations at the project site. A bolus followed by an infusion will help maintain
consistency among providers, prevent missing administration of the second bolus, and provide
weight-based dosing to limit side effects.
CPIT Committee Presentation
The Clinical Practice Guideline Recommendations were presented to the
Surgery/Anesthesia CPIT committee via a virtual meeting on November 23, 2021. The project
proposal and guideline recommendations were provided to the committee prior to the
presentation for review. The project proposal and guideline recommendations were also
forwarded on to the Cardiac CPIT committee for review and distribution to the cardiac team.
Feedback from the committee included clarification on current practices involving TXA
and EACA. The clarification was made that EACA is the standard antifibrinolytic used at this
institution, however, if there is a medication shortage TXA is an acceptable substitution. For this
reason, it is important that the institution has guidelines in place for the use of both
antifibrinolytic medications. There are no current plans for implementation of the guidelines but
there may be consideration in the future.
Limitations
There were several limitations to this project. Data collection and analysis of outcomes
such as blood loss, blood transfusions, and reoperation were outside the scope of this project.
This limitation prohibited the assessment and determination of current practice efficacy. The
literature provided no consensus on ideal dosing for TXA or EACA. The recommendations
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provided were based on dosing previously studied in the literature as well as current pharmacy
prescribing guidelines at the institution. Due to academic/curricular time limits for the scholarly
project, the current project team was unable to complete implementation of the guideline at the
project site.
Conclusion
Despite strong evidence from the literature for best practices and well-established
international standard ERAS guidelines, reports from key stakeholders from pharmacy and
anesthesia departments at the project site revealed that the use of antifibrinolytic administration
is not consistently practiced within the cardiac surgical setting. Additionally, the anesthesia and
pharmacy department stakeholders reported that a lack of an evidence-based practice guideline
may be contributing to the lack of antifibrinolytics administration in some patients. However, the
extent of any clinical data demonstrating any adverse outcomes were unknown. The project
team conducted a chart audit to demonstrate a clinical problem and support the need for the
proposed aims of this project. Review of the anesthesia records revealed a variation in dosing of
EACA, limited use of TXA, and omission of antifibrinolytic administration in patients that met
the standards for the use of TXA or EACA. Consequently, the lack of standardized guidelines
aligned to the EBP recommendations by the ERAS Cardiac Surgery Society for antifibrinolytic
medication administration for on pump cardiac surgery and subsequent variability of clinical
practice validated by recent chart audit may be indicate an increased risk to cardiac surgical
patients for adverse outcomes related to bleeding, blood transfusions, and the need for
reoperation.
Therefore, the purpose of this project was to provide the hospital site leadership with
recommendations to help streamline and improve the quality and consistency of ERAS guided
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practices involving antifibrinolytic medications in cardiac surgical patients. The objectives
outlined and described previously were met as indicated by the completion of this scholarly
project. Ultimately, the findings of this scholarly project can serve as a beginning point for
improved identification of current practice gaps as well addressing the needs of anesthesia
providers and pharmacy caring for these cardiac surgical patients. The submission and future
implementation of a standardized, evidence-based, clinical practice guideline may improve
anesthesia practices and patient outcomes centered on using standardized ERAS protocols for
administering antifibrinolytics to cardiac surgery patients.
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Mannminutes
baseline
than 60
Whitney U
after
(before
mL/min,
test was used
protamine
initiation of
with
for data
administrati
EACA
expected
comparisons.
on. The
infusion),
decreases in
P values less
median
(2) 5
the
than 0.05
change in
minutes
clearance of
were
Ddimer
after CPB
EACA and
considered
(DD-dimer)
initiation,
D-dimer
statistically
from
(3) 30- tosignificant
baseline to
45 minutes
for all tests
15 minutes
after CPB
Eligible
after
initiation,
patients
protamine
(4) 15
were adults
was 0.34
minutes
having
(0.48 to
after
elective
3.81) mg/L
protamine,
coronary
FEU. DDand
(5)
1artery
dimer did
to2
hours
bypass
not
after the
grafting
correlate
end of
(CABG),
with EACA
EACA
mitral valve
concentrati
infusion.
repair or
on
replacement
intraoperati
(MVR),
vely, urine
aortic valve
output,
replacement
body
(AVR),
weight,
and/or
glomerular
ascending
filtration
aorta
rate, cell
replacement
salvage
with
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anticipated
time on
CPB of 120
minutes or
less.

volume,
and
ultrafiltrati
on volume.
The median
24-hour
chest tube
output was
445 (1801,011) mL.
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Appendix B
Clinical Guideline Recommendation Template

Specialty CGC

Approval Month + Year

Clinical Guidance Council Guideline

Guideline Title
GUIDELINE TITLE
OhioHealth is supportive of the following guideline from XXX:
+ Guideline
+ Additional points
+ For the most up-to-date version of the guideline, visit URL

WHY?

WHAT IS A
GUIDELINE?
A guideline recommends how
something should be done based upon
evidence-based and/or best practice
(e.g., Clinical Guidelines or Drug Use
Guidelines) while permitting variation
according to clinical judgment and the
unique facts presented.

ACTION REQUIRED

Reason behind the approval of the guideline. What problem was

Use this as a guide for your practice.

identified?

Unique circumstances and need for
individualization of care may
require appropriate deviation from
these guidelines.

MEASURES OF SUCCESS
This guideline intends to improve the delivery of patient care.
While adherence to the guideline and clinical outcomes may not
be tracked regularly, an improvement should be noticed in the following
metrics:

APPROVAL
This guideline was approved
by the following Clinical Guidance
Councils:
+ Subcouncil name, date (XX/XXXX)
+ Main CGC, date (XX/XXXX)

+ Measure
+ Measure
+ Measure

CONTACT
For questions, contact:
SME name, credentials
SME title
SME e-mail

REFERENCES
List current references used
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Appendix C
TXA SWOT Analysis
Strengths:
•

•

Weakness:

1-A strong recommendation from

•

No consensus on optimal dosing

Cardiac ERAS Society

•

Only one patient received TXA in the

Reduced blood transfusions and
reoperation for major hemorrhage or

data collection
•

tamponade
•

Not commonly used at project site for
cardiac surgery

Weight-based, low-dose strategy
appears to be safer

•

Provides alternative to EACA if
medication shortage occurs

Opportunities:
•

Large, double-blinded, randomized

Threats:
•

controlled trial currently being
completed to identify dosing with max
efficacy and minimal complications
•

Education for staff on TXA benefits

Dose dependent adverse effects of TXA
administration: stroke and seizures

•

Support from cardiothoracic surgeons
and anesthesia staff
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EACA SWOT Analysis
Strengths:
•

Main antifibrinolytic used at project site

•

Support from multiple professional
organizations for routine use

Opportunities:
•

Weakness:
•

Omission in cases that meet standards
for administration of an antifibrinolytic

•

Variation in dosing

•

Possible subtherapeutic dosing

Threats:

Improve the quality and consistency of

•

Support from cardiothoracic surgeons

EACA dosing

•

Buy in from anesthesia to use consistent
dosing
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Appendix D
OhioHealth Nursing Evidence-Based Practice Committee (NEBPRC) Approval
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.1~11- OhioHealth

Chris Foltz BSN, SRNA
Katonya Lawson BSN, SRNA
Otterbein University
April29 , 2021

RE: ERAS for Cardiac Surgery: Development ofa Clinical Practice Guideline for
Antifibrinolytic Administration in Cardiac Surgery
Dear Ms. Lawson and Mr. Foltz:
The Nursing Evidence-Based Practice Review Committee (NEBPRC) has reviewed the
proposal referenced above. Clear evidence was submitted to justify both the need for the
practice change and that evidence supports the proposed plan. You have adequately
addressed all concerns from the pre-review and the revisions are accepted.
The NE BPRC has determine that the project proposal you submitted does not meet the
Federal definition of research as cited in CFR 45-46: 102. According to the Federal Code,
research is defined as:
(I) Research means a systematic investigation, including research development,
testing, and evaluation , designed to d evelop or contribute to generalizable
knowledge. Activities that meet this definition constitute research for purposes of
this policy, whether or not they are conducted or supported under a program that is
considered research for other purposes.
You have permission to develop the evidenced-based guideline as written. Upon
completion of the project and before dissemination (poster or manuscript), you must
submit the results so that the OhioHealth can review the presentation to ensure Health
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Appendix E
Otterbein University Institutional Review Board Approval

('
,
.h
OTTERBEIN
\Lill
UN IVE RS ITV

INSTITUTIONAL REVIEW BOARD

__X__ Original Review
_____ Continuing Review
_____ Amendment

Dear Dr. Garrett,
With regard to the employment of human subjects in the proposed research:
HS # 20/21-69
Garrett, Foltz, Lawson & Sribanditmongkol: ERAS for Cardiac Surgery: Development …
THE INSTITUTIONAL REVIEW BOARD HAS TAKEN THE FOLLOWING ACTION:
We have determined that the proposed activity is not characterized as human subjects
research, in that the investigators are not:
1. Obtaining information or biospecimens through intervention or interaction with the
individual, and using, studying, or analyzing the information or biospecimens; or
2. Obtaining, using, studying, analyzing, or generating identifiable private information or
identifiable biospecimens.
Therefore, IRB review is not required.

Date: _________________________
(Revised January 2019)

Signed: __________________________________
Chairperson
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Appendix F
Clinical Guidance Council Recommendation Guidelines

Cardiac Surgery Anesthesia CGC

Approval Month + Year

Clinical Guidance Council Guideline
Administration Tranexamic Acid (TXA) for On-Pump Cardiac Surgery

ADMINISTRATION OF TRANEXAMIC ACID (TXA)
FOR ON-PUMP CARDIAC SURGERY
Tranexamic Acid (TXA)
+ Synthetic antifibrinolytic and analog of lysine
+ Antifibrinolytic medications have been shown to decrease blood loss as well as

the need for blood transfusions and reoperation
Pharmacodynamics
+ Competitively inhibits the activation of plasminogen to plasmin

WHAT IS A
GUIDELINE?
A guideline recommends how
something should be done based upon
evidence-based and/or best practice
(e.g., Clinical Guidelines or Drug Use
Guidelines) while permitting variation
according to clinical judgment and the
unique facts presented.

+ Plasmin is responsible for degradation of fibrin clots, fibrinogen, and other

plasma proteins
Pharmacokinetics
+ 100% bioavailability with IV administration
+ 95% excreted unchanged in urine
+ Half-life (IV) of 2 hours; increased in renal impairment

ACTION REQUIRED
Use this as a guide for your practice.
Unique circumstances and need for

+ Duration of 7-8 hours

individualization of care may

+ Administer over a minimum of 10 minutes to avoid transient lowering of blood pressure

require appropriate deviation from

Indications

these guidelines.

+ Acute fibrinolytic bleeding associated with on-pump cardiac surgery
+ No current recommendations for routine use in off-pump cardiac surgery

Current OhioHealth Prescribing Guideline

APPROVAL

+ 1g loading dose administered before sternotomy followed by a constant

This guideline was approved
by the following Clinical Guidance
Councils:

intravenous infusion at 400 mg/hr until sternal closure
+ Addition of 500 mg to the cardiopulmonary bypass circuit
+ Infusion rates in cardiac surgery should be lowered in renal impairment
+ Reduce by 25% if SCr 1.6-3.3; reduce by 50% if SCr 3.3-6.6; reduce by

75% if SCr > 6.6

+ Subcouncil name, date (XX/XXXX)
+ Main CGC, date (XX/XXXX)

Optimal Dosing in the Literature
+ Guidelines regarding patient blood management recommend the routine

use of tranexamic acid for adult cardiac surgery, however, no consensus
exists on the dosing regimen to be administered
+ Low-dose TXA, total dose approximately < 20 mg/kg, appears sufficient

to reduce post-operative blood loss and blood transfusion (Zufferey et al., 2021)
+ 10 mg/kg bolus followed by 1 mg/kg/hr over 12 h

CONTACT
For questions, contact:
SME name, credentials
SME title
SME e-mail

+ Single pre-operative bolus of 20 mg/kg
+ Low-dose TXA, bolus injection < 50 mg/kg or 10 mg/kg + 1 mg/kg/hr (Guo et al.,

2019)
+ High dosing at approximately 100 mg/kg has little effect in reducing transfusion

requirement and tends to cause more seizure attacks, though “high-dose” varies
greatly in the literature (Guo et al., 2019)
Practice Change Recommendation
+ Consider lowering dosing practices of TXA to reflect literature low-dose regimen
+ 10 mg/kg pre-operative bolus + 1 mg/kg/hr over 12 h or single pre-operative

bolus of 20 mg/kg
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Clinical Guidance Council Guideline
Administration Tranexamlc Acid (TXA) for On-Pump Cardiac Surgery
CAUTIONICONTRAINOICATIONA
TXAallorgy

cau11on to patlUfllS w!th major renal, hQ,patle, and ca,Ul~e eomorb!!d!tJes, thoso using rnediCOUO(\s 11tfoellng tiemostasis, ~hoso
w,th know oongu-1®othy1 th<>ao w'ilh .1m abnorm~I 0011,gututlon protllo, thoeio with rocun\ coronury atontlng, and thOIO with 11,
h!sto,y or thfomboucnbolls..-n duu to oommonly being oxctucwd from TXA caru!ac surgury trials.
Svtflclont dflti t-& availublo to \nk>fm TXA adtnlnlstr.etlon lo pationts Of thos:o common oxclusfon calOOOf'IOS (Khalr ot al , 2019

WHY1
r 110 An\ortcan t:oltugo o4 Card!.Clltlgy FounaauuNAmuncan MOa1t Assocmt1on. Amudta.11 S6c!uty bl A116slhosioWyJsl8.
European Assoaauon tor C-ardioU,01c:ieic Surgery, tho Soeiety ~, Thoracic Surr,>eonsJAmctican Association for Thoracic
surpory, und tho EMS oa,dlac Suroory Soctoty havu pubtlistit>d rooommundstlon11 and gulduUn,uv f0t tho rouUoo uso ot
antrtbnnolyUcli to roduco btoodlng 1 btood tmnwtu110n11 u" d rt1opo,u~on1 (Of on~pump cardia,o 1u,vory,
MEASURES OF SUCCESS
Thia guldelln1 lntond1 to lmprov1 the dollvory of p.atlont c.aro. WhlJe adheronce to the gulOOUne and cllnlc1111
ou1comoa may not bo tracked roguJ1rly1 an lmprovomont ahould b1 notlcod tn tho foUowlng mo1rlc1:
+ Consist()nt <losir.g asnor.g aoosthesia pr0-.,!do,s and surgoor.s
.j.

Es<malod blood IOSS (ml)

1 Oh>uOt1a111tullon ,oqu11on1ot1li1
+ Ro-oper~L.on duos lo ma;.or hamorrhage or cardiac tampon.ado
REFERENCElr
tsoer, C., Pagano, o., Meeste,s, M. L, Mlk>jev!c, M,, IU!'1deuo, U,, tk>Urget; o., Heymann, t., Je.ppsson, A., Koster, A., Osnabrvgge1
ll l.. Ranu«i, M.. Kavn, H.. Vonk, A. a., & Wahba, A. {2018). 2017 EACfS/EACTA Guidelines on patient blood management for
1d1,1lt c:ardfa, sur(Sery, Jouin• Iof C1rd!ott'tor•clc il'!d Vam,lar AnHthesli, 3'2, $8'- UO
£n1elm1n, o. r.. AU, w., W!IUl"'Ji. J. 6.• Pen1utt, L
. P.• fled dv. V,i Arora, It c.• "'°HIii, £. e,, Kltoy,nuhad, A.. GtrdJsth, M.. Levy. ,.
H.• Lobdell, It , f letcher, N., l(usch, M., Ne-Ison, G., l!ngetman, ft. M., Gregory, A.J.., & Boyle, E. M, (2019). Guldeli:nes for
PerTcperative Care In Card!a~ Surgery: Enhanced ft«overy After surgery SoQMV Recommendations. JAMA Surge,y, 154(8), 755IGG. hnp,://dol.orll/10.1001/J• masurc.2019.11SI
(Juo1 J,, 0101 le-1 Mt, 'V,, LY, Ii,, 11u, \V,, lha.ng. S., Jl1 H., Want. G., & Shl1 J (2019t, O,tlt ttnt dcu.e ttg:lmes ~nd ldmlnl1tt~bon
methods of ttane.xamk acid (n cardiac surgery: A meta-analysis of randomized trials. 81'4CAnesthesiology, 19(129), l --'16.
httpsj/dol.org/10.1186/s'l 2311-0t 9 -0l12-0

IOI.Ir,. S., ,,ertlmn, I., 't'1te,, J,, f,tvfor, J. L1mpron, j,, Tinmouth, A.. & Stldtnberg, E', 12019), bdu,ion cnttr!JI 1nd 1dv1:r1e
c~.nts In petloper-1tlve uials of ttll'!e.itam1c acid In cudlac wrger,.: a systtm•tlc Ht'l'i&w and me twnalys!s. Conodlon Journal of
Anesrhesia, 66, 1240--llSO. https://dol.org/10.1007/st2630-019-01393~w
A.aphae-1, t, Maze,, C., Subrama~~ S., Schroeder1 A., Abdalla, M, Ferreira, R., Roman, P, E., Pilte~ N,, Wehby, I,, Gre1Uc~ ,., E.,
H1Nti1 A,, kanll(cl1 M,1 Hol.tr1 L Q.., 8otr, C,, WUkti, A,, i-ilU, S. E., Nutt1II, Q. A,, P1lvtdi1 11, ft,1 P11t~l1 fJ, A!j, LI\J1 W, jiOIO),
Soctetv o( ca,tt)O\lakulcr Anesthestolo,lsu d ln.lcal practice ¥nipr0\leme/1t adV11Qry tot ma.na.iement c t perioperaUve ble-!dlng
and hemostasls lO cardiac surgery patients. Journal of CardJothorock and Vascular Anesthesia, 33, 288'/- 2899.
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Cardiac Surgery Anesthesia CGC

Approval Month •· Year

Clinical Guidance Council Guideline
Administration of Epsilon Amlnocaprolc Acid (EACA) for On-Pump Cardiac Surgery

ADMINISTRATION OF EPSILON AMINOCAPROIC
ACID (EACA) FOR ON-PUMP CARDIAC SURGERY
Epsilon Amlnocaprolc Acid (EACA)

+ Synthetic anllf,brtnolyUo and analog or lysine
+ Antifibrinolytic medications have been shown io decrease blood
1088

as well as lhe need for blood transfusions and reoperallon,

Pharmacodynamlcs
+ Competitively lnhlblls the acllvatlon or plasmlnogen lo plasmln.
+ Plasmin Is responsible for degradation of fibrin clots, fibrlnogen,
end other plasma ptotelns

WHAT IS A
GUIDELINE?
A gul<1uhno rueommunda how
something shOu-Jd be done based upon
uvldonco-.ba!Wct and/or bast practice
(u,Q.. Cl•1tlc..l GulOu'li10• ur D1ug U••
Guld•ltnos) wh,lc permitting varlatlon
according to c:on1ca1 Judgmem and the
unlquo tnct11 prosontod,

ACTION REQUIRED
Use this as a glllide for your practtco.
Unique eircumstanc.aa and noad for
lndMduaJtuUon o f CDtOml)'

Pharmacoklnetlcs

require appropriate dGVlat.lon from

+ Eliminated unCl!anged by lhe kidneys

thne guld ollnea,

+ Hair-life" unknown
+ Peak blood levels - 2 hours
+ Plasma levels greater then 130mg/L are necessary 10 Inhibit
fibrlnolysls.

APPROVAL

w••

Thi& guldotlno
app1ovod
by lho following Cltnlcal Guidanoo

Coundts.

Indications

,

+ Acute fibrlnolytic bleedli,g associated with on-pump cardiac surgery ,
~

Suboouncll nomo, dato (XX/XXXX)
Main CGC, oat• (XX/XXXX)

No current recommendations for routine use In or(-pump cardiac
surgery

CONTACT

Precautions and Contraindications

For qu11tlon11cofltactt

+ Loading doses and boluses should be administered over 15-60

SME namo1 crod<lnMl!i
SMEIIIIC
SME O.rnall

minutes
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Clinical Guidance Council Guideline
Administration of Epsilon Amlnocaprolc Acid (EACA) for On-Pump Cardiac Surgery

OhloHealth Recommended Dosing

+ 5-10 g or 75-150 mg/kg loading dose rollowed by 1 g/hr or 10-15 mg/kg/hr IV
f

10 g bolus, repeated up lo 3x (10 g + 10 g +10 g)

T

Max daily dose Is 30 g

Optimal Dosing In the Literature
t 10g loadlng dose, ro11owed by 2glhr tnrusion
(Fergusson et al., 2006 and Levy el al., 2016)

+ 10-15mg/kg loading dose, followed by 1-2m!)lk!)"hr ror 6 hours
+ bolus dose for bypass clrcoll 2•3mgll<g (Blaine el al., 2016)

Current Practice at Grant Medical Center
+ 10g bolus dose, repealed up to 2x. VariaUon In repeated dosing.

+ Flrst bolus prior to bypass and second dose post bypass,
Practice Change Recommendation

+ 10g boh1s dose, followed by an Infusion el 10-16mg/kg/hr
+ Maintains oonsistency among providers

+ Eliminates missing seoond bolus ener bypass
+ Helps maintain steady stale of drug concentration In blood

WHY?
The American College of cardiology Foundation/American HeartAssoclaUon, American Society or
Anesthesiologists, European Association ror Cardlothoraclc Surgery, the Society of
Thoraolo Surgeons/American Association for Thoracic Surgery, end the ERAS Cardiac Surgery Society
have publrshad reoommendatJons and guidelines ror the routine use of anUfibrinolyllcs to reduce bleeding,
blood transfusions, and reoperalions for on-pump cardiac surgery.
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